1. A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment. Issue 6 (27th April 2017) Authors: Chacra, Antonio; Gantz, Ira; Mendizabal, Geraldine; Durlach, Lucila; O'Neill, Edward A.; Zimmer, Zachary; Suryawanshi, Shailaja; Engel, Samuel S.; Lai, Eseng Journal: International journal of clinical practice Issue: Volume 71:Issue 6(2017) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗